Generation, Characterization and Epitope Mapping of Two Neutralizing and Protective Human Recombinant Antibodies against Influenza A H5N1 Viruses

Lina Sun1, Xiuhua Lu2, Chuan Li1, Min Wang3, Qinzi Liu1, Zi Li3, Xiaofen Hu1, Jiandong Li3, Feng Liu1, Qun Li4, Jessica A. Belser2, Kathy Hancock2, Yuelong Shu3, Jacqueline M. Katz2, Mifang Liang1*, Dexin Li3,

1 State Key Laboratory for Infectious Disease Control and Prevention, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China, 2 Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 3 State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China, 4 Anhui Provincial Center for Disease Control and Prevention, Hefei, China

Abstract

Background: The development of new therapeutic targets and strategies to control highly pathogenic avian influenza (HPAI) H5N1 virus infection in humans is urgently needed. Broadly cross-neutralizing recombinant human antibodies obtained from the survivors of H5N1 avian influenza provide an important role in immunotherapy for human H5N1 virus infection and definition of the critical epitopes for vaccine development.

Methodology/Principal Findings: We have characterized two recombinant baculovirus-expressed human antibodies (rhAbs), AVFluIgG01 and AVFluIgG03, generated by screening a Fab antibody phage library derived from a patient recovered from infection with a highly pathogenic avian influenza A H5N1 clade 2.3 virus. AVFluIgG01 cross-neutralized the most of clade 0, clade 1, and clade 2 viruses tested, in contrast, AVFluIgG03 only neutralized clade 2 viruses. Passive immunization of mice with either AVFluIgG01 or AVFluIgG03 antibody resulted in protection from a lethal H5N1 clade 2.3 virus infection. Furthermore, through epitope mapping, we identify two distinct epitopes on H5 HA molecule recognized by these rhAbs and demonstrate their potential to protect against a lethal H5N1 virus infection in a mouse model.

Conclusions/Significance: Importantly, localization of the epitopes recognized by these two neutralizing and protective antibodies has provided, for the first time, insight into the human antibody responses to H5N1 viruses which contribute to the H5 immunity in the recovered patient. These results highlight the potential of a rhAbs treatment strategy for human H5N1 virus infection and provide new insight for the development of effective H5N1 pandemic vaccines.

Citation: Sun L, Lu X, Li C, Wang M, Liu Qz, et al. (2009) Generation, Characterization and Epitope Mapping of Two Neutralizing and Protective Human Recombinant Antibodies against Influenza A H5N1 Viruses. PLoS ONE 4(5): e5476. doi:10.1371/journal.pone.0005476

Introduction

Multiple distinct and geographically diverse genotypes of highly pathogenic avian influenza (HPAI) A H5N1 viruses now exist and continue to cause outbreaks of disease in domestic poultry on three continents [1,2]. The occasional spill-over of HPAI H5N1 virus into humans has, since late 2003, resulted in over 387 confirmed human cases of H5N1 influenza of which 245 have been fatal [3]. H5N1 viruses are now endemic in multiple countries in parts of Asia, Africa, and possibly the Middle East [2]. Accordingly, these viruses pose a substantial public health threat; if H5N1 viruses acquire the ability to spread efficiently in humans lacking antibody-mediated immunity to the H5 surface protein, a pandemic would result. If the virus retains its current virulence for humans, an H5N1 pandemic would have catastrophic consequences.

Influenza A viruses are enveloped RNA viruses in the family Orthomyxoviridae possessing eight negative-sense genomic segments and are classified into subtypes based on their two surface glycoproteins, the hemagglutinin (HA) and neuraminidase (NA). There are 16 known HA and 9 NA subtypes that exist in aquatic birds, the natural reservoir of all influenza A viruses [4,5,6]. Currently circulating HPAI H5N1 viruses arose from a progenitor virus isolated in China in 1996 [7]. Since 1997, ten distinct clades (0-9) of H5N1 viruses have been recognized based on the phylogeny of the H5 HA gene [7]. Clade 0 viruses caused the 1997 Hong Kong outbreak of human disease, whereas the human cases associated with the reemergence of H5N1 viruses in Southeast Asia in 2003–2005 were a result of infection with Clade 1 viruses. H5N1 Clade 2.1 viruses are now endemic in Indonesia, whereas Clade 2.2 viruses spread from Qinghai Lake,
China in 2005, and are now found in birds in Western Asia, the Middle East, Europe and Africa and have caused fatal human disease in these respective regions. Clade 2.3 H5N1 viruses have played a dominant role in outbreaks in China and adjacent countries in 2005–2007 [2,8,9] and have resulted in recent human fatalities in Vietnam and Laos [2,3]. The multiple clades and subclades of H5N1 viruses causing human disease are also antigenically distinguishable, which poses a considerable problem for H5N1 human vaccine development, since influenza vaccines offer optimal protection when the vaccine strain is a close antigenic match with the circulation virus causing disease [10,11,12]. Moreover, treatment options for H5N1 virus-infected patients remain limited and empirical, and resistance of newly emergent H5N1 viruses to either of the two classes of licensed antiviral drugs, further hampers effective treatment [9,13,14]. Therefore, the development of new therapeutic targets and strategies to control H5N1 virus infection in humans is urgently needed.

Neutralizing antibodies directed against the HA glycoprotein are the primary mediator of protection against influenza virus infection [15,16]. Three HA monomers, each consisting of an HA1 and an HA2 subunit, form the trimeric HA spike protruding from the viral membrane. The HA1 subunit contains the receptor-binding site which mediates viral attachment to the cell membrane, whereas, the HA2 subunit contributes to membrane fusion [17,18]. Passive immunization with human monoclonal antibodies (mAbs), humanized mouse mAbs or equine Fab fragments specific for HA has been reported to be effective in protecting animals from death from influenza, even when administrated after H5N1 virus infection [19,20,21]. Indeed, there is some evidence that passive immunotherapy may be administrated after H5N1 virus infection [19,20,21]. Furthermore, through epitope mapping, we identify two distinct epitopes on H5 HA molecule recognized by these rhAbs and demonstrate their potential to protect against a lethal H5N1 virus infection in a mouse model. These results highlight the potential of a rhAbs treatment strategy for human H5N1 virus infection and provide new insight for the development of effective H5N1 pandemic vaccines.

**Results**

**Generation of two recombinant human antibodies against H5N1 viruses**

A combinatorial antibody library, prepared from a 26 year old donor who was infected with H5N1 virus 14 weeks earlier, was screened with purified AH/1/05 clade 2.3 virus. After four rounds of panning, 43 human Fab clones were selected which demonstrated reactivity with AH/1/05 purified virus by ELISA. Sequence analysis of all 43 selected Fab clones revealed the presence of only two unique clones, both of them comprising an IgG1 Fd heavy chains and lambda light chains. As shown in Table 1, a Fab antibody designated AVFluFab01 represented 18 Fab clones that possessed a unique VH4 and VL2 sequences, while the antibody designated AVFluFab03 represented the other 25 Fab clones that possessed distinct VH3 and VL3 sequences. To further characterize the two Fabs, the two unique Fab clones were converted into intact human IgG antibodies, AVFluIgG01 and AVFluIgG03.

**Characterization of AVFluIgG01 and AVFluIgG03 in vitro and in vivo.**

The AVFluIgG01 and AVFluIgG03 binding properties were characterized using indirect immunofluorescence assay (IFA), micro-neutralization assay (MN), and hemagglutination inhibition assay (HI) assays, and in vivo by passive immunization study in BALB/c mice.

To further identified the relative binding specificities and binding regions, the two rhAbs previously shown to bind to AH/1/05 whole virus in ELISA were tested by IFA with MDCK cells infected with H5N1, H3N2, or H1N1 virus (Figure 1A), or SF-9 cells expressing rHA, rHA1 or rHA2 of AH/1/05 virus (Figure 1B). A serum sample from the H5N1 virus-infected patient reacted with H5N1 AH/1/05 and contemporary human influenza A viruses, HB/53/05 (H1N1) and YN/1145/05 (H3N2); and also reacted with rHA, rHA1, and rHA2 of AH/1/05 virus (Supplemental Figure S1). Both AVFluIgG01 and AVFluIgG03 reacted with AH/1/05 virus, but exhibited no reactivity with human H3N2 and H1N1 viruses (Figure 1A). Additionally, both

| Table 1. Amino acid sequences of variable regions in the H and L chains of H5N1 virus-specific Fabs |
|---------------------------------------------------------------|
| **Fabs** | **VR** | **CDR1** | **CDR2** | **CDR3** |
| AVFluFab01 | VH | GYYWS | YLFDSGTSNYP5LTS | RFWGDLGFDI |
| | VL | TGTSSDVGDYNYVYS | DVKDRPS | SSYS5SSTWV |
| AVFluFab03 | VH | DYM5 | AIGNGGGSTYYADS5KG | DDSYDGGCCYGHLHWNFDS |
| | VL | TGSSSNGAGYDVH | GNSNRP5 | QSYDSLSLVF |

*VR, variable region: VH, heavy chain in VR; VL, light chain in VR.

**CDR, complementarity determining region.

doi:10.1371/journal.pone.0005476.t001
rhAbs reacted with rHA or rHA1 of AH/1/05 virus, but exhibited no reactivity with H5 HA2 region (Figure 1B).

To evaluate the neutralizing activities of the two rhAbs, MN assays were performed first using clade-2.3 and clade-2.2 H5N1 viruses isolated from patients from China (Table 2). With a single exception, AVFlulgG01 showed neutralizing activity against all of the clade 2.3/2.2 viruses tested with the 50% neutralizing antibody concentrations ranging between 1.3–5.2 µg/ml; no AVFlulgG01 neutralizing activity was detected against the clade 2.3 virus, A/Guangdong/1/06 (GD/1/06). In contrast, AVFlulgG03 neutralized all clade 2.3 strains including GD/1/06, and also neutralized the clade 2.2 (XJ/1/06) virus, but required approximately 10-fold more antibody compared with AVFlulgG01 to achieve 50% neutralization. In a second experiment, the rhAbs were tested for their ability to cross-neutralize multiple H5N1 viruses, representing clade 0, 1, 2.1, 2.2 and 2.3 which have all been associated with human disease to date (Table 3). Interestingly, while AVFlulgG01 exhibited broad cross-neutralization of all viruses tested, AVFlulgG03 had no detectable cross-neutralizing activity against the clade 0 and clade 1 viruses tested. The neutralizing activity of the rhAbs against the clade 2.3 virus AH/1/05 were again similar in this experiment, and likewise, the neutralizing activity of AVFlulgG01 against a clade 2.2 virus (Turkey/15/06) was again 10-fold higher than that observed for AVFlulgG03. Taken together, these data demonstrate distinct binding patterns of the two rhAbs for epitope(s) within the HA1 domain of H5N1 viruses.

To confirm the reactivity patterns of AVFlulgG01 and AVFlulgG03, HI activities against H5N1, H3N2, and H1N1 viruses were assessed (Table 4). The results of the HI assays were consistent with those achieved by the MN assays in that AVFlulgG01 reacted broadly with all H5N1 viruses tested in a concentration range of 1.6–3.1 µg/ml, whereas, AVFlulgG03 reacted in a similar concentration range with all clade 2 viruses, but failed to inhibit hemagglutination of clade 0, and clade 1 H5N1 viruses (Table 3). Lack of binding activity between AVFlulgG03 and rHA of clade 0 and clade 1 H5N1 viruses was

### Table 2. Neutralization activity of recombinant human antibodies against influenza A H5N1 viruses isolated from China

| Viruses used             | Genetic clades | Concentrations (µg/ml)* |
|-------------------------|----------------|------------------------|
|                         |               | AVFlulgG01      | AVFlulgG03      |
| A/Xinjiang/1/06 (XJ/1/06)| 2.2           | 1.3                  | 12.5             |
| A/Anhui/1/05 (AH/1/05)  | 2.3           | 1.3                  | 0.8              |
| A/Guangxi/1/05 (GX/1/05)| 2.3           | 2.6                  | 3.1              |
| A/Fujian/1/05 (FJ/1/05) | 2.3           | 2.6                  | 1.6              |
| A/Sichuan/1/06 (SC/1/06)| 2.3           | 5.2                  | 0.8              |
| A/Hunan/1/06 (HN/1/06)  | 2.3           | 1.3                  | 0.8              |
| A/Zhejiang/1/06 (ZJ/1/06)| 2.3          | 5.2                  | 3.1              |
| A/Guangdong/1/06 (GD/1/06)| 2.3        | >500                 | 1.6              |

*The 50% neutralizing antibody concentrations (µg/ml) resulting from the MN assays.
also observed in ELISA assays (Supplemental Table S1). Furthermore, the HI assays confirmed the lack of reactivity of either rhAbs for contemporary human influenza A viruses of the H1N1 and H3N2 subtypes.

To investigate the protective efficacy of prophylaxis by passive immunization with AVFluIgG01 and AVFluIgG03, BALB/c mice were administered 2.5, 0.25 or 0.025 mg/kg of either rhAb or 10 mg/kg of a control human IgG1 antibody (HIgG1), 24 hr prior to challenge i.n. with 10 LD50 (=10^4.5MID50; =10^5.5EID50) of AH/1/05 wild-type virus. As shown in Figure 2, all mice receiving the control HIgG1 succumbed to the lethal H5N1 virus by day 10 post-infection (p.i.). In contrast, mice that received prophylaxis with a single 2.5 mg/ml dose of AVFluIgG01 or AVFluIgG03 were completely protected from lethal disease (p < 0.0006). A dose-dependent decrease in protective efficacy was observed in mice receiving 10- or 100-fold lower amounts of either rhAb. Although the lower doses of AVFluIgG01 or AVFluIgG03 did not completely prevent fatal disease, they delayed time to death (p < 0.05). Nevertheless, even at a dose of 0.025 mg/kg, the AVFluIgG03 protected 50% of mice from lethal disease (p = 0.045). Although lung and brain virus titers determined 6 days p.i. were reduced (≥3-fold) in mice that received 2.5 mg/kg of either rhAb compared with those receiving the control HIgG1, these differences did not achieve statistical significance (Supplemental Table S2). These results demonstrate that passive immunization of mice with either anti-H5 clade 2.3 rhAb resulted in protection from lethal H5N1 virus disease.

### Table 3. Neutralization activity of recombinant human antibodies against H5N1 viruses isolated from China and other countries

| Viruses used       | Genetic clades Concentrations (μg/ml) a | AVFluIgG01 | AVFluIgG03 |
|--------------------|----------------------------------------|------------|------------|
| A/HongKong/156/97  (HK/156/97)       | 0  0.4  >500                               |            |            |
| A/Viet Nam/1203/04 (VN/1203/04)      | 1  0.8  >500                               |            |            |
| A/Indonesia/5/05 (Indo/5/05)         | 2.1 12.5  6.3                              |            |            |
| A/Turkey/15/06 (Turkey/15/06)        | 2.2 0.4  6.3                               |            |            |
| A/Anhui/1/05 (AH/1/05)               | 2.3 0.8  0.2                               |            |            |

aMinimum concentrations of rhAbs that required to neutralize the 50% infectivity of 100 TCID50 of viruses were determined by Micro-neutralization (MN) assay.

### Table 4. HI activity of recombinant human antibodies against influenza A H5N1, H3N2, and H1N1 viruses

| Influenza A Viruses used | Subtypes | Genetic clades | Concentrations (μg/ml) a | AVFluIgG01 | AVFluIgG03 |
|--------------------------|----------|----------------|----------------------------|------------|------------|
| HK/156/97                | H5N1     |                |                            | 0  1.6     | >250       |
| VN/1203/04               | H5N1     |                |                            | 1  1.6     | >250       |
| Indo/5/05                | H5N1     |                |                            | 2.1 3.1    | 3.1        |
| Turkey/15/06             | H5N1     |                |                            | 2.2 1.6    | 3.1        |
| XJ/1/06                  | H5N1     |                |                            | 2.2 3.1    | 3.1        |
| AH/1/05                  | H5N1     |                |                            | 2.3 1.6    | 1.6        |
| GX/1/05                  | H5N1     |                |                            | 2.3 1.6    | 1.6        |
| FJ/1/05                  | H5N1     |                |                            | 2.3 1.6    | 1.6        |
| JX/1/05                  | H5N1     |                |                            | 2.3 1.6    | 1.6        |
| SC/1/06                  | H5N1     |                |                            | 2.3 1.6    | 1.6        |
| A/Fujian/1/07            | H5N1     |                |                            | 2.3 1.6    | 3.1        |
| A/Wyoming/3/03           | H3N2     |                | NA b                       | >250       | >250       |
| A/New Caledonia/20/99    | H1N1     |                | NA b                       | >250       | >250       |

aMinimum concentrations, in micrograms per milliliter (μg/ml), that required to completely inhibit 4 HA units of virus were determined by HI assay by using 1% of horse erythrocytes for H5N1 virus or 0.5% of turkey erythrocytes for human H3N2 and H1N1 viruses.

bNA, not applicable.

doi:10.1371/journal.pone.0005476.t003

doi:10.1371/journal.pone.0005476.t004

Figure 2. Protective efficacy of AVFluIgG01 and AVFluIgG03 in mice. BALB/c mice (n = 6 per group) were passively immunized by i.p. injection of graded doses of rhAbs, AVFluIgG01 or AVFluIgG03, or human IgG1 (HlgG1) as a negative control (NC). Mice were challenged i.n. with 10 LD50 (=10^4.5MID50; =10^5.5EID50) of AH/1/05 virus 24 h later. The data show the Kaplan-Meier survival curves for the 21 days p.i. Mice that received 2.5 mg/kg of either AVFluIgG01 or AVFluIgG03 were completely protected from a lethal challenge (rhAbs versus HlgG1, p = 0.0006, log rank test). Both rhAbs also afforded partial protection and delayed days to death at lower doses of 0.25 mg/kg and 0.025 mg/kg (rhAbs versus HlgG1, p > 0.05, log rank test). Both rhAbs also afforded partial protection and delayed days to death at lower doses of 0.25 mg/kg and 0.025 mg/kg (rhAbs versus HlgG1, p = 0.0006, log rank test). Both rhAbs also afforded partial protection and delayed days to death at lower doses of 0.25 mg/kg and 0.025 mg/kg (rhAbs versus HlgG1, p = 0.0006, log rank test). Both rhAbs also afforded partial protection and delayed days to death at lower doses of 0.25 mg/kg and 0.025 mg/kg (rhAbs versus HlgG1, p = 0.0006, log rank test). Both rhAbs also afforded partial protection and delayed days to death at lower doses of 0.25 mg/kg and 0.025 mg/kg (rhAbs versus HlgG1, p = 0.0006, log rank test). Both rhAbs also afforded partial protection and delayed days to death at lower doses of 0.25 mg/kg and 0.025 mg/kg (rhAbs versus HlgG1, p = 0.0006, log rank test).
Epitope mapping

To identify the potential individual amino acids essential for interaction with the two cross-neutralizing human antibodies, amino acid sequences of HA1 region of some human H5N1 isolates used above in the MN and/or HI assays were aligned (Table 5) and analyzed in the context of the respective rhAbs binding reactivity and the antigenic sites previously identified on the H5 HA1 molecule [19,30,31]. AVFluIgG01 showed broad cross-neutralizing reactivity to all H5N1 representatives of clade 0, clade 1 and clade 2 viruses except the clade 2.3 virus GD/1/06 (Table 2). Sequence alignment of HA1 proteins identified two amino acid substitutions at position 123 and 183 (S123P and D183N) that were unique to GD/1/06 virus compared with AH/1/05 virus and other clade 2.3 H5N1 viruses tested with which AVFluIgG01 reacted (Table 5). On the other hand, AVFluIgG03 had failed to react with clade-0 and clade-1 viruses by the MN and horse HI assays (Table 3 and Table 4) and also failed to bind clade 0 (HK/156/97) and clade-1 (VN/1203/04) rHA by ELISA (Supplemental Table S1). As illustrated in Table 5, sequence alignment of the HA1 regions identified eight amino acid differences in the clade 0 and clade 1 viruses compared with the clade 2 H5N1 viruses at positions D124S/N, E126D, S129L, Q138L, T140K, P141S, N155S, and T156A. Therefore, we next investigated whether each of these amino acid positions contributed to the antibody-binding epitopes recognized by AVFluIgG01 and AVFluIgG03, respectively.

To test the impact of the above identified changes of amino acid substitutions identified in natural H5N1 strains, we generated AH/1/05 rHA gene products possessing single amino acid substitutions as identified above (Table 5) and expressed in 293T cells. The ability of the AVFluIgG01 and AVFluIgG03 to bind to the mutated rHA proteins was detected by IFA. As a control for expression, the IFA reactivity of the polyclonal patient serum was also determined for each mutated protein. As shown in Table 6, the mutation S123P resulted in the complete loss of binding of AVFluIgG01 to the expressed rHA product. In contrast, the other substitution that was unique to GD/1/06, D183N, had no effect on the binding of the AVFluIgG01. For AVFluIgG03, mutations at E126D, S129L, and N155S abolished or substantially reduced binding of the AVFluIgG03 to the rHA antigen. The remaining substitutions, D124S/N, Q138L, T140K, P141S, and T156A, had no effect on the binding of either AVFluIgG01 or AVFluIgG03 to expressed rHA. The results indicated that the amino acid residue at position 123 was critical for the binding of AVFluIgG01, while Glu<sup>126</sup>, Ser<sup>129</sup> and Asn<sup>155</sup> were important for the binding of AVFluIgG03.

WB analysis demonstrated that AVFluIgG01 reacted with the denatured virul HA1 protein. In contrast, AVFluIgG03 showed no

### Table 5. Amino acid changes in HA1 of the H5N1 viruses isolated from humans

| Viruses (clade) | HI and/or MN<sup>a</sup> | Amino acid positions<sup>b</sup> |
|----------------|----------------------|-------------------------------|
|                | AVFluIgG01          | AVFluIgG03                    | 123 | 124 | 126 | 129 | 138 | 140 | 141 | 155 | 156 | 183 |
| HK/156/97 (0)  | +                    | -                             | S   | N   | D   | S   | L   | R   | S   | S   | A   | D  |
| VN/1203/04 (1) | +                    | -                             | S   | S   | E   | L   | Q   | K   | S   | S   | T   | D  |
| Inda/5/05 (2.1)| +                    | +                             | D   | E   | S   | L   | S   | P   | S   | T   | D  |
| Turkey/15/06 (2.2)| +                  | +                             | D   | E   | S   | Q   | R   | S   | N   | A   | D  |
| XJ/1/06 (2.2)  | +                    | +                             | S   | D   | E   | S   | Q   | T   | P   | N   | T   | D |
| AH/1/05 (2.3)  | +                    | +                             | P   | D   | E   | S   | Q   | T   | P   | N   | T   | N  |

*"++", indicates positive binding; "-", indicates negative binding in HI and/or MN assays.

<sup>a</sup>Amino acid numbering is based on H5 HA.

### Table 6. Epitope mapping of rhAbs to a panel of site mutant rHA of AH/1/05

| Mutant site<sup>a</sup> | AVFluIgG01 | AVFluIgG03 | PC |
|-------------------------|------------|------------|----|
| rHA of wild type        | +++        | +++        | +++|
| Q115G                   | +++        | +++        | +++|
| I116H                   | –          | –          | ++ |
| I117P                   | –          | –          | ++ |
| P118S                   | ++         | +++        | +++|
| K119G                   | +++        | +++        | +++|
| S120N                   | +          | +++        | +++|
| S121A                   | +          | +++        | +++|
| W122G                   | –          | –          | ++ |
| S123P                   | –          | +++        | +++|
| D124S/N                 | +++        | +++        | +++|
| H125Y                   | ++         | +++        | +++|
| E126D                   | ++         | –          | ++ |
| A127V                   | +++        | +++        | +++|
| S128Y                   | +++        | +++        | +++|
| S129L                   | +++        | –          | +++|
| Q138L                   | +++        | +++        | +++|
| T140K                   | +++        | +++        | +++|
| P141S                   | +++        | +++        | +++|
| K152G                   | –          | –          | ++ |
| K153G                   | +++        | +++        | +++|
| N154G                   | +++        | +++        | +++|
| N155S/G                 | ++         | /          | +  |
| T156A/G                 | +++        | +++        | +++|
| D183N                   | +++        | +++        | +++|

<sup>a</sup>The amino acid mutant positions are in H5 numbering.

<sup>b</sup>IFA were performed on 293T cells transfected with mutant rHA constructions. (++) to (+++) indicates the relative intensity of fluorescence.

doi:10.1371/journal.pone.0005476.t006
binding activity with denatured HA1 (Figure 3). The WB result suggested that the epitope recognized by AVFluIgG01 may be a linear epitope, while the epitope recognized by AVFluIgG03 may be a conformational epitope. In an effort to further map the respective epitopes bound by these rhAbs, we generated an additional series of rHA mutants and tested the ability of both rhAbs to bind to the expressed rHA products by IFA. Except for two highly conserved amino acids (Lys119 and Trp122), each selected amino acid was replaced by a corresponding variable amino acid identified in wild-type human H5N1 virus strains emerging in Asia and Africa respectively (Influenza Virus Resource: http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html). The two conserved amino acids were replaced with Glycine (G). To further delineate the binding epitope of AVFluIgG01, single amino acid substitutions around Ser123, from HA1 residues 115 to 129 were constructed. Mutations at I116H, I117P, P118S and W122G resulted in complete loss of AVFluIgG01 binding; moreover, mutations at S120N and S121A resulted in substantially reduced binding of AVFluIgG01, but had no impact on the binding of the polyclonal patient’s serum (Table 6). In contrast, substitutions at Q115G, K119G, D124S/N, H125Y, E126D, A127V, S128Y and S129L had no or little effect on the binding of this rhAb. These results are consistent with the AVFluIgG01 epitope being linear and comprised of HA1 residues 116–123. Interestingly, the mutations at I116H, I117P, and W122G also led to the abolishment of AVFluIgG03 binding. To further investigate the likely conformational epitope for AVFluIgG03, we analyzed the three-dimensional structure of the H5 HA molecule (Figure 4) and the structure prediction of the H5 A/Anhui/1/2005 HA1 by modeling were created with the software Discovery StudioTM 2.0(Accelrys, USA) and the H5 A/Anhui/1/2005 HA1 structure was obtained from the crystal structure of the highly related the H5 A/Viet Nam/1194/2004 HA1 (PDB accession number 2BX) by DS MODELER (Discovery Studio 2.0). Amino acid positions are designated in H5 numbering. We noted that amino acids Lys152, Lys153, Asn154, Asn155, Thr156, which are close to Glu126 and Ser129, were selected for glycine scanning mutagenesis assay. As shown in Table 6, glycine substitution at K153G, N154G and T156G have little or no effect on the binding for AVFluIgG03. In contrast, the N155G mutations resulted in a notable reduction in AVFluIgG03 binding, whereas the K152G mutation completely abolished AVFluIgG03 binding, in a manner similar to mutations I116H, I117P, and W122G. Therefore, three non-continuous regions, designated site I (Ile116, lle117, Trp122), site II (Glu126, Ser129) and site III (Lys152, Asn155), likely contribute to the non-continuous conformational epitope for AVFluIgG03.

Discussion

In the present study, we generated two H5N1-specific rhAbs (AVFluIgG01 and AVFluIgG03) representing the repertoire of Fab clones recovered from the blood of a convalescent H5N1 virus-infected patient (Table 1 and Figure 1). Interestingly, convalescent plasma from this same patient who had donated the blood for generating hAbs a few weeks earlier was used to transfuse a critically ill patient infected with a genetically similar H5N1 virus; the passive immunotherapy recipient subsequently recovered [32,33]. Furthermore, as demonstrated in this study, the rhAbs were confirmed to protect mice from lethal H5N1 disease (Figure 2), suggesting that they may represent the dominant B cell response in the recovered H5N1 virus-infected patient. Generation of such human antibodies provides not only important insight into the protective immune response to H5N1 virus in humans, but also provides a valuable treatment option for future H5N1 virus-infected patients [32,34,35].

The immune reactivity profile showed that AVFluIgG01 had broad cross HI and/or neutralizing activity in vitro against all viruses tested except one clade 2.3 virus, GD/1/06 in which one amino acid substitution (S123P) was implicated in the loss of reactivity with this virus (Table 2–4). On the other hand, AVFluIgG03 showed a more narrow HI and neutralizing profile in that it failed to react with clade 0 and clade 1 viruses, but exhibited strong and broad cross activity for all 2005 and 2006 clade 2 virus strains tested (Table 2, Table 3, Table 4). Both rhAbs gave 50% neutralization of H5N1 viruses in the 0.2–12.5 μg/ml range and protected 100% of mice from fatal disease at a dose of 2.5 mg/kg, doses that were comparable to the virus-neutralizing and lowest in vivo protective concentrations of human H5-specific mAbs derived from memory B cells of a clade 1 H5N1 virus-infected patients reported elsewhere [21]. Although we observed an antibody dose-dependent reduction in viral load in the lung and brain tissue, our results did not achieve statistical significance, at this antibody dose (2.5 mg/kg) that conferred complete protection from death. It should be noted that, where other studies have demonstrated significant reduction in viral load in lung and brain tissues in mice given human H5 antibody prophylaxis, the doses used to demonstrate protection were up to 8 times higher than the dose that gave complete protection from death in our study [21].
Figure 4. Schematic representation of the epitopes recognized by AVFlulgG01 and AVFlulgG03 on the globular head of the H5 AH/1/05 HA1 molecule. Amino acid positions are designated in H5 numbering. A linear epitope (IIPKSSWS, amino acid 116–123) recognized by AVFlulgG01 is colored in red; non-continuous conformational epitope of AVFlulgG03 is colored in blue; the overlapping binding site for both AVFlulgG01 and AVFlulgG03 are colored in green. The receptor binding domain (RBD) is highlighted with a purple oval. (A) Side view of the HA1
We predict that, had we used higher doses of antibody, or a less stringent challenge dose, we would have observed a significant correlation between reduction in viral load and survival. Further studies are needed to address the mechanism of antibody action in protection from death. Our previous studies in mice have suggested that a reduction in extrapulmonary spread is important in survival from H5N1 virus infection [41]. The mouse model used in this study described the primary functionality of the antibodies, we are planning more detailed studies to address the prophylactic or therapeutic potential of these antibodies, either alone or in combination, for their ability to protect from severe disease induced by homologous H5N1 virus, as well as heterologous H5N1 viruses of other clades. We think that it would help to understand the relevance of the epitopes and their mode of action.

The epitopes recognized by AVFluIgG01 or AVFluIgG03 were on the head of the HA1, but not HA2 molecule and appeared to be linear or conformational, respectively (Figure 1 and Figure 3). Sequence alignment and site-directed mutagenesis of HA (AH/1/05) identified amino acid residues that were critical for the binding activity of the two H1-specific rhAbs (Table 5 and Table 6). For the linear epitope recognized by AVFluIgG01, alignment of the H5N1 viruses HA1 used in MN assays revealed that GD/1/06 HA1 differed in 2 amino acids (S123P, D183N) from the wild-type AH/1/05 and/or other clade 2.3 H5N1 viruses, thereby providing important insight as to the location of the linear epitope. The results of site-directed mutagenesis indicated that the linear epitope for AVFluIgG01 was contained within a sequence of IPIKSSWS (amino acid 116–123 of HA1) and identifies for the first time a linear neutralizing antigenic epitope recognized by H5N1 patient-derived human antibody, of which the critical amino acid residues (Ile116, Ile117, Pro118, Trp122, Ser125) were not reported previously. Interestingly, mutations I116H, I117P and W122G also abolished AVFluIgG03 binding. Furthermore, by examining the positions of the AH/1/05 HA1 sequences on three-dimensional H5 HA structure as illustrated in Figure 4, we observed that this newly defined linear epitope recognized by AVFluIgG01 (colored in red and green) (Figure 4A and 4B) comprises a remarkably tight cluster on the exposed surface of the globular head of the HA1 H5 molecule, forming a ridge that protrudes prominently from the H5 HA1/05 HA1 surface, that is in close proximity to the receptor binding region (RBD), which comprises 190 helix, 130 loop and 220 loop as colored in pink in Figure 4A and 4B [31,36]. The position of the surface-exposed epitope is consistent with a direct role of AVFluIgG01 in neutralizing virus infectivity through binding the epitope on the HA spike and block attachment of virus to the receptor. Moreover, by performing bioinformatics analysis, using the 266 human H5N1 virus strains available in the database of Influenza Virus Resource (http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html), we found that residues Lys119 and Trp122 were absolutely conserved while other residues in the proposed linear epitope were partially buried at the surface of the globular head of the HA1 and may contribute through stabilizing and/or positioning of the linear epitope on the globular head of the HA1 H5 molecule. We propose that this novel linear epitope defined by the broadly neutralizing human antibody AVFluIgG01 represents a highly conserved neutralization epitope that may play an important role in inducing protective humoral immune responses to H5N1 viruses in humans. In contrast to the continuous epitope identified by AVFluIgG01, the epitope recognized by AVFluIgG03, is comprised of three non-continuous sites which comprise a conformational determinant as illustrated in blue and green in Figure 4 (A, B, D, and E), from the top view of the H5 three-dimensional structure (Figure 4B and 4E). Site I (Ile116, Ile117 and Trp122) in green, partially overlaps with the linear epitope identified by AVFluIgG01 but is not exposed from the upper surface of the H5 HA molecule, suggesting that this site may not directly interact with the AVFluIgG03 but may otherwise affect the stability of the conformational epitope on the globular head of the HA1 H5 molecule. Site II (Glu126 and Ser129) overlaps with a previously described antigenic site 3 in H5 HA based on the X-ray crystallographic structure of the clade 1 virus VN/1203/04 virus [30,31] and is adjacent to the Sa site defined in the H1 subtype based on the antigenic structure analysis of A/Puerto Rico/8/34 virus with mouse mAbs [26]. Site III (Lys152, Asp155) partially corresponds to the previously identified antigenic site 2 in the H5 HA [29,30] and site B in the H3 HA structure [25]. Both site II and the site III are exposed on the upper surface of the H5 HA molecule and are located along the upper edge of receptor-binding domain pocket (RBD; in purple) (Figure 4A and 4B). Residues 126, 129 and 155 were initially implicated in the binding of AVFluIgG03 since differences at these positions were identified between the 2005 clade 2.3 AH1/1/05 and the clade 0 and clade 1 viruses which failed to react with the AVFluIgG03 by MN and HI tests (Table 2–4). Site-directed mutagenesis of AH/1/05 HA confirmed that the residues Glu126 and Ser129 were critical residues for the binding of AVFluIgG03. Interestingly, the H5 epitope for the human antibody AVFluIgG03 overlaps with epitopes recognized by mouse mAbs on a mouse-adapted duck H5N2 virus (A/Mallard/Pennsylvania/10218/84) identified by the sequence analysis of virus escape mutants [29,30]. Using a similar approach, amino acid residue 152 was identified as a key position within the epitope recognized by certain mouse mAbs on the clade 1 H5N1 virus VN/1203/04 HA [30]. These results suggest that the conformational antigenic determinant defined here may be a key region for drift variation among H5N1 viruses that have infected humans.

In summary, we have generated and characterized two recombinant baculovirus-expressed human neutralizing and protective antibodies directed against an H5N1 clade 2.3 virus which exhibit unique properties for intra and inter-clade virus reactivity. Importantly, localization of the epitopes recognized by the two rhAbs has provided, for the first time, insight into the human antibody responses to H5N1 viruses which contribute to the H5 immunity in the recovered patient. The primary prophylactic functionality of the antibodies were addressed in this study with the mouse model. More detailed studies in vivo would help to understand the significance of the defined epitopes and the important mechanisms for prophylaxis or therapy of human infection with H5N1 viruses. The utility of the recombinant approach allows for rapid scale-up in production, as well as a
means to rapidly clone and express antibodies with specificity for newly emerging H5N1 variants. More functional human antibodies could be obtained by additional screenings. The rAbs described here alone or in combination with other functional human antibodies may provide a promising strategy against human H5N1 virus infection.

**Materials and Methods**

**Viruses**

Influenza viruses used in this study were propagated at 37°C in the allantoic cavity of 10-day-old embryonated hens’ eggs for 26 hours (H5N1 virus) or 48 hours (H3N2 and H1N1 viruses), and were aliquoted and stored at −70°C until use. Fifty percent egg infectious dose (EID50) titers were determined by serial titration of virus in eggs and calculated by the method of Reed and Muench [37]. A/Anhui/1/2005 (AH/1/05) virus was propagated in MDCK cells. Culture supernatants were clarified by low-speed centrifugation to remove cell debris, and were further purified by using continuous sucrose density gradient ultracentrifugation.

**Generation of recombinant human antibodies to H5N1 virus**

Lymphocytes used for mRNA extraction were isolated from blood that was collected from a 26-year-old female convalescent H5N1 virus-infected patient from Anhui province. The blood donor developed symptoms on 11 February 2006 following contact with diseased poultry [22,33] and convalescent blood was obtained 14 weeks after the onset of a disease. The written informed consent was agreed by the patient. Total cellular mRNA was extracted and cDNA was synthesized. The heavy and light chain genes were amplified from the cDNAs by PCR and sequentially cloned into the phagemid vector pComb3H. The H5N1 virus-infected patient antibody phage library was constructed by using primers and methods as previously described [38]. The antibody library was screened by panning on purified AH/1/05 virus [39]. After three or four rounds of panning, crude Fab antibody preparations were tested by indirect ELISA using 96 well plates coated with 0.5–1 μg of purified AH/1/05 virus. HRP-conjugated anti-human Fab was used as the secondary antibody. The selected human Fab antibody genes were sequenced and two of them were converted to human IgG by cloning the Fab genes into IgG expression cassette vectors pAc-L-Fc as previously described [40]. The two rAbs (AVFluIgG01 and AVFluIgG03) were expressed in SF9 cells and purified on a Protein A column for further characterization and functional analysis. Purity of rAbs was confirmed using SDS-PAGE analysis.

**Construction and expression of rHA, rHA1, and rHA2**

The viral RNA was extracted from AH/1/05 virus and the cDNA was synthesized. The DNA fragments encoding full length HA, HA1 or HA2 were amplified by RT-PCR and cloned into pAcUW51 vector (BD Biosciences) and then expressed in SF9 cells. Cells were grown in 24 wells plates and were then either directly stained in the wells or were prepared as monolayer on glass slides followed by acetone fixation. Bound antibodies were detected by using FITC-conjugated anti-human antibodies and observation under an immunofluorescence microscope.

**Immunofluorescence Assay (IFA)**

IFAs were performed on different cells according to the experimental design. To measure rAbs reactivity for viral antigens, Madin Darby Canine Kidney (MDCK) cells were infected respectively with AH/1/05 (H5N1), A/Hubeihongshan/55/2005 (HB/55/05; H1N1), and A/Yunnan/1145/2005 (YN/1145/05; H3N2) viruses. To measure rAbs reactivity for viral recombinant HA (rHA), rHA1, or rHA2, SF-9 cells were infected with recombinant baculoviruses expressing HA, HA1 or HA2 products from AH/1/05 virus, respectively. To evaluate rHA containing site-directed mutations, rHAs were transiently expressed in 293T cells. Cells were grown in 24 wells plates and were then either directly stained in the wells or were prepared as monolayer on glass slides followed by acetone fixation. Bound antibodies were detected by using FITC-conjugated anti-human antibodies and observation under an immunofluorescence microscope.

**Microneutralization assay**

To verify the neutralizing ability of AVFluIgG01 and AVFluIgG03 against avian H5N1 or human H3N2 and H1N1 viruses, the HI assays were performed using 0.5% turkey red blood cells for detecting reactivity with human H3N2 and H1N1 virus [44] or 1% horse red blood cells for detecting reactivity with avian H5N1 viruses [45]. HI antibody titers are expressed as the concentrations of rAbs that gave 50% neutralization of 100 50% tissue culture infectious dose (TCID50) of virus in MDCK cells.

**Hemagglutination-inhibition (HI) assay**

To verify the HI ability of AVFluIgG01 and AVFluIgG03 against avian H5N1 or human H3N2 and H1N1 viruses, the HI assays were performed using 0.5% turkey red blood cells for detecting reactivity with human H3N2 and H1N1 virus [44] or 1% horse red blood cells for detecting reactivity with avian H5N1 viruses [45]. HI antibody titers are expressed as the concentrations of rAbs that completely inhibited 4 hemagglutinating units (HAU) of virus.

**Passive immunization of mice and challenge experiment**

The fifty percent mouse infectious dose (MD50) and 50% lethal dose (LD50) of AH/1/05 virus were determined as previously described [46]. To evaluate the degree of protection, 8 week-old female BALB/c mice (Jackson Laboratories, Bar Harbor, MA, USA) were intraperitoneally (i.p.) injected with 0.5 ml of purified rAb preparations of various concentrations or hyperimmune rabbit antiserum raised against baculovirus expressed H5 rHA of A/Vietnam/1203/2004 virus (VN/1203/04) (Protein Sciences Corporation, Meriden, CT, USA) as a positive control (PC). Negative control (NC) antibody was a purified human myeloma IgG1 (Sigma, Missouri, USA). Twenty-four hours after passive immunization, mice were lightly anesthetized by inhalation of CO2 and challenged intranasally (i.n.) with 10 LD50 (= 104 MID50; 102.5 EID50) of AH/1/05 virus in 50 μl. Mice were monitored daily for sickness, weight loss and death for 21 days.

**Western blot (WB) analysis**

Purified virus of AH/1/05 was applied to 10% SDS-PAGE and transferred to a PVDF membrane with a mini-protein apparatus (Bio-Rad). The denatured antigens were probed with patient sera (1:150 dilution) as a PC or 1 μg/ml of an anti-SARS IgG as a NC or the two rAbs at 1 μg/ml. A goat anti-human IgG conjugated to HRP was used as the secondary antibody. The reaction was detected by ECL reagent (Pierce) according to the manufacturer’s instructions.

**Amino acid substitutions by site-directed mutagenesis**

Mutagenic primers were designed after aligning sequences of HAs region of MN and HI tested human H5N1 isolates including A/Anhui/1/2005 (Genebank accession DQ371928), A/Guangxi/1/2005 (DQ371930), A/Hunan/1/2006 (FJ492879), A/Zhejiang/1/2006 (FJ492880), A/Sichuan/1/2006 (FJ492881), A/Fujian/1/2005 (FJ492882), A/Fujian/1/2007 (FJ492883), A/Guangdong/1/2006 (FJ492884), A/Jiangxi/1/05 (FJ492885), A/Xinjiang/1/2006
Schematic representation of the epitopes recognized by AVFluIgG01 and AVFluIgG03 on the globular head of the H5 HA1 molecule

The H5 AH/1/05 HA1 structure was based on the crystal structure of the highly related the H5 A/VietNam/1194/2004 HA1 (PDB accession number 2IBX) by DS MODELER (Discovery Studio 2.0). Images were created with the software Discovery StudioTM 2.0 (Accelrys, USA).

Statistical analysis

Kaplan-Meier survival curves and logrank tests were used to measure differences between rHAs treated mice and NC mice.

References

1. WHO (2005) Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 11: 1515–1521.
2. Abdel-Ghafar AN, Chotipatyasunondh T, Gao Z, Hayden FG, Nguyen DH, et al. (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 359: 861–873.
3. WHO Cumulative Number of Confirmed Human Cases of Avian Influenza A/ (H5N1) Reported to WHO. 2008 (http://www.who.int/csr/disease/avian_influ enza/country/cases_table_2008_06_19/en/index.html).
4. Assaad FB, et al. (1980) A revision of the system of nomenclature for influenza viruses: a WHO Memorandum. Geneva: WHO. Bulletin World Health Organization 58: 583–591.
5. Kohl C, Zhou N, Suss J, Mackenzie J, Webster RG (1996) Characterization of a novel influenza hemagglutinin, H15: criteria for determination of influenza A subtypes. Virology 217: 508–516.
6. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, et al. (2005) Rapidly evolving avian influenza A/H5N1 viruses: the genetic basis for virulence of A/Goose/Guangdong/1/96 (H5N1) virus. Virology 316: 445–453.
7. Xu X, Subbarao K, CJ, Gao Y (1999) Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 261: 15–19.
8. Dung Nguyen T, Vainh Nguyen T, Vijaykrishna D, Webster RG, Guan Y, et al. (2008) Multiple sublineages of influenza A virus (H5N1), Vietnam, 2005-2007. Emerg Infect Dis 14: 639–646.
9. Webster RG, Govorkova EA (2006) H5N1 influenza—continuing evolution and spread. N Engl J Med 355: 2174–2177.
10. Cox N, R HL (1996) Global influenza surveillance: Tracking a moving target in a rapidly changing world. In: Brown LE HA, Webster RG, eds. Options for the control of influenza III: Elie Science. pp 591–598.
11. Wood JM, Robertson JS (2004) From viral life to saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2: 842–847.
12. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM (2004) Continuing the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 4: 499–509.
13. de Jong MD, Tran TT, Truong HK, Yo MH, Smith GJ, et al. (2005) Oshima coronavirus resistance during treatment of influenza A (H1N1) infection. N Engl J Med 353: 2607–2672.
14. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: isolation of drug-resistant H5N1 virus. Nature 437: 1108.
15. Wiley DC, Skehel JJ (1967) The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 56: 363–394.
16. Mozdzierz K, Feng J, Gerhard W (2003) Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice. J Virol 77: 6322–6328.
17. Eisen MB, Sabesan S, Skehel JJ, Wiley DC (1997) Binding of the influenza A virus to cell-surface receptors: structures of five hemagglutinin-sialyloligosaccharide complexes determined by X-ray crystallography. Virology 232: 19–31.
18. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69: 531–569.
19. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, et al. (2006) Passive immunoprophylaxis and mice. Respir Res 7: 126.
20. Lu J, Zhao Z, Pan X, Wang G, Zhang D, et al. (2006) Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin Fab’2 in mice. Respir Res 7: 43.
21. Simmons CP, Bernasconi NL, Squitain AL, Mills K, Ward JM, et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4: e178.
22. Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza (H5N1) infection. N Engl J Med 357: 1450–1451.
23. Kashyap AK, Steed J, Omer AF, Dillon MA, Scwar EE, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal neutralizing antibody neutralization strategies. Proc Natl Acad Sci U S A 105: 5906–5911.
24. Bai HH, Peters B, Assarsson E, Mhawech I, Sette A (2007) Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A 104: 246–251.
25. Wiley DC, Wilson IA, Skehel JJ (1981) Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 299: 373–378.
26. Caton AJ, Brownlie GG, Yewdell JW, Gerhard W (1982) The antigenic structure of the influenza virus A/PR/8/34 haemagglutinin (H1 subtype). Cell 51: 417–427.
27. Tsuichika E, K. S, S, H, Y, M, Y, et al. (2001) Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus. J Gen Virol 82: 2475–2485.
28. Hilpott M, Hoo C, Sheikh M, Hishaw VS (1990) Hemagglutinin mutations related to attenuation and altered cell tropism of a virulent avian influenza A virus. J Virol 64: 2941–2947.
29. Kaverin NV, Rudneva IA, Lysnova IA, Argunovich IA, Lipatov AS, et al. (2002) Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J Gen Virol 83: 2497–2505.
30. Kaverin NV, Rudneva IA, Govorkova EA, Timofeeva TA, Shalov AA, et al. (2007) Epitope mapping of the haemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 81: 12911–12917.
31. Reid JJ MH (1938) A simple method for estimating fifty percent end points. Am J Hyg 1938; 27: 493–497.
32. Kong LK, Zhou BP (2006) Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 12: 489.
33. Barbas CF 3rd, Kang AS, Lerner RA, Benkovic SJ (1991) Assembly of selected antibody fragments. J Immunol Methods 247: 119–130.

Supporting Information

Table S1

Found at: doi:10.1371/journal.pone.0005476.s001 (0.04 MB DOC)

Table S2

Found at: doi:10.1371/journal.pone.0005476.s002 (0.03 MB DOC)

Figure S1

Found at: doi:10.1371/journal.pone.0005476.s003 (2.25 MB TIF)

Acknowledgments

We thank Dr. Hong Xu and Dr. Yue Wang for useful discussion and advise; We thank Dr. Shumin Duan for using BSL-3 facility. We are grateful to Prof. Zhijie Liu from Institute of Biophysics, Chinese Academy of Sciences for superb technical assistance in 3D structure analysis.

Author Contributions

Conceived and designed the experiments: LS XL YS JMK ML DL. Performed the experiments: LS XL CL MW QL ZL XH JL FL QL JAB KH. Analyzed the data: LS XL JL FL KH YS JMK ML DL. Contributed reagents/materials/analysis tools: KH YS JMK ML DL. Wrote the paper: LS XL JMK ML DL.
36. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, et al. (2006) Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine. Vaccine 24: 2176–2185.

37. Nwe N, He Q, Damrongwatanapokin S, Du Q, Manopo I, et al. (2006) Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture. BMC Microbiol 6: 16.

38. Rowe T, Abernathy RA, H-P J, Thompson WW, Lu X, et al. (1999) Detection of antibody to avian influenza A (H3N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37(4): 937–943.

39. Kendal AP, Skehel JJ, Pereira MS (1982) Concepts and procedures for laboratory-based influenza surveillance. B17-B35. Centers for Disease Control, Atlanta, Ga. Kendal AP, Pereira MS, Skehel J.

40. Stephenson I, Wood JM, Nicholson KG, Zambon MC (2003) Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 70: 391–398.

41. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, et al. (1999) A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73: 5903–5911.

42. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006) Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312: 404–410.

43. Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antiviral Res 47: 57–77.

44. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV (2004) Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 25: 306–310.

45. Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13: 602–614.

46. Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, et al. (2004) The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303: 1838–1842.